HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Jackie Centeno

Jackie Centeno

Clinical Program Director

Jackie Centeno serves as Genprex’s Clinical Program Director, where she is responsible for the management and day-to-day operational aspects of clinical studies, including internal and external services to support milestone achievement. Ms. Centeno has more than 15 years of oncology clinical research experience working within both the CRO and biotech space. Prior to joining Genprex, Jackie spent three years managing multiple early phase oncology studies for a boutique CRO, LumaBridge and two years managing several oncology studies at Heat Biologics (now Nighthawk Biosciences). Early in her career she worked in the CRO industry at both PRA Health Sciences and ICON Clinical Research. Ms. Opiola graduated from University of South Florida with a Bachelor of Science in Biology.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Announces IP Australia’s Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers Feb 10
  • Genprex Provides Clinical Update on Diabetes Gene Therapy Program Jan 7
  • Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Jan 6
  • Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer Nov 24
Designed and Secured by Barsec
Copyright ©2026 all rights reserved.
Home - Privacy Policy - Terms of Use